Bataille R, Grenier J, Sany J
Anticancer Res. 1987 May-Jun;7(3 Pt B):513-5.
Measuring serum beta-2-microglobulin (B2M) in 90 patients with multiple myeloma (MM) from diagnosis to death (83 cases), or to the terminal phase of their disease (7 cases), we have obtained evidence that 9% of them retained normal serum B2M levels during the whole of their follow-up. This was observed in 6 IgA MM, in one light chain MM only and in one non-secretory MM. These data suggest a lack of B2M production and/or secretion by some myeloma tumors. This could limit the use of B2M as clinical marker in MM.
在90例多发性骨髓瘤（MM）患者中，从诊断直至死亡（83例）或疾病终末期（7例），我们检测了血清β2微球蛋白（B2M），发现其中9%的患者在整个随访期间血清B2M水平保持正常。6例IgA MM、1例轻链MM和1例非分泌型MM中观察到了这种情况。这些数据表明，一些骨髓瘤肿瘤缺乏B2M的产生和/或分泌。这可能会限制B2M作为MM临床标志物的应用。
